Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14233382 | 1.00 | KMT2A (0.51) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL9527531 | 0.98 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL2913896 | 0.98 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL15151056 | 0.98 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL18364935 | 0.98 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL6906651 | 0.98 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL7057539 | 0.98 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL8854257 | 0.98 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL8498418 | 0.98 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL20128999 | 0.96 | KMT2A (0.49) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109678818-B | Method for synthesizing aggregation pheromone (E) -cis-6,7-epoxy-2-nonenal of taurus communis | 常州大学 | 2020-06-16 | — | — | CN | claimed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-11485812-B2 | Pyranoquinazoline derivatives and naphthopyran derivatives | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2022-11-01 | — | — | US | disclosed |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-10-06 | — | — | US | disclosed |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-08-04 | — | — | US | disclosed |
| CN-109678818-B | Method for synthesizing aggregation pheromone (E) -cis-6,7-epoxy-2-nonenal of taurus communis | 常州大学 | 2020-06-16 | — | — | CN | disclosed |
| US-20200131193-A1 | PYRANOQUINAZOLINE DERIVATIVES AND NAPHTHOPYRAN DERIVATIVES | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-0465835-A1 | Anionic living polymers, their derivatives and composition comprising them | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1992-01-15 | — | — | EP | disclosed |
| US-5053548-A | Containing hydroxy substituents; nervous system disorders | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| US-4977267-A | ANTISECRETORY AGENT | FUJIREBIO KABUSHIKI KAISHA (JP) | 1990-12-11 | — | — | US | disclosed |
| EP-0382213-A2 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4912101-A | Containing a secondary amide, suflur group and a furan ring | FUJIREBIO KABUSHIKI KAISHA (JP) | 1990-03-27 | — | — | US | disclosed |
| US-4849436-A | TREATMENT OF CARDIOVASCULAR DISORDERS | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0282077-A2 | Pyridyloxy derivatives | FUJIREBIO KABUSHIKI KAISHA (JP) | 1988-09-14 | — | — | EP | disclosed |
| EP-0259462-A1 | 1,4-DIHYDROPYRIDINES | Whitby Research Incorporated (US) | 1988-03-16 | — | — | EP | disclosed |
| WO-1987005512-A1 | 1,4-DIHYDROPYRIDINES | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1987-09-24 | — | — | WO | disclosed |
| EP-0183177-A1 | Unsaturated fatty acid derivatives and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | KMT2A 1250/4885MEN1 1944/4885KDM4C 2111/4885 |
| US-11485812-B2 | Pyranoquinazoline derivatives and naphthopyran derivatives | PPOX, TYR, NQO1 | KMT2A 1709/4885MEN1 4432/4885KDM4C 496/4885 |
| US-20200131193-A1 | PYRANOQUINAZOLINE DERIVATIVES AND NAPHTHOPYRAN DERIVATIVES | PPOX, TYR, NQO1 | KMT2A 1829/4885MEN1 4353/4885KDM4C 615/4885 |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | KMT2A 3113/4885MEN1 1520/4885KDM4C 1908/4885 |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | KMT2A 3113/4885MEN1 1520/4885KDM4C 1908/4885 |
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | RPN2, MPDU1, RPN1 | KMT2A 4395/4885MEN1 2947/4885KDM4C 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.